Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00086125 · ClinicalTrials.gov registry record · Phase 2
Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)
A Phase 2 study of Lymphoma and Leukemia, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 2
- Development phase
- 57
- Enrollment target
- 8
- Study locations
NCT00086125: Completed Phase 2 study of Lymphoma and Leukemia, sponsored by Merck Sharp & Dohme.
NCT00086125 is a Phase 2 study of Lymphoma and Leukemia that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 57 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (88% lower). The trial reports 8 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00086125, a Phase 2 study of Lymphoma and Leukemia, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 57 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this phase II study is to assess the efficacy of AP23573 in patients with specified relapsed or refractory hematological malignancies.
Conditions Studied
Interventions
- DRUG ridaforolimus
Study Locations (8)
Illinois
- University of Chicago Hospitals, Section of Hematology/Oncology - Chicago
Missouri
- Washington University School of Medicine, Siteman Cancer Center, 4921 Parkview Place - St Louis
New Jersey
- The Cancer Institute of New Jersey - New Brunswick
New York
- New York Presbyterian Hospital, Weill College of Cornell University - New York
North Carolina
- Morris Cancer Center - Duke University Medical Center, Adult Bone Marrow Transplant Clinic - Durham
Ohio
- Gabrail Cancer Center - Canton
Pennsylvania
- Jeane's Hospital of TUHS - Philadelphia
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2004-06 |
| Est. Completion | 2006-06 |
| Phase | Phase 2 |
What the finished NCT00086125 record still lists
NCT00086125 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (88% lower).
The record links to 5 conditions, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which ridaforolimus is the first listed.
NCT00086125 lists 8 locations in 8 states (Illinois, Missouri, New Jersey).
Frequently Asked Questions
What is clinical trial NCT00086125 about?
NCT00086125 is a clinical study titled "Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)". The purpose of this phase II study is to assess the efficacy of AP23573 in patients with specified relapsed or refractory hematological malignancies.
What is the current status of trial NCT00086125?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2004-06. Estimated completion is 2006-06.
What conditions does trial NCT00086125 study?
This clinical trial studies the following conditions: Lymphoma, Leukemia, Myelodysplastic Syndromes, Hematologic Malignancies, Myeloid Metaplasia.
What interventions are being tested in trial NCT00086125?
The interventions under investigation include: ridaforolimus (DRUG).
Who is sponsoring clinical trial NCT00086125?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00086125 being conducted?
This trial has 8 study locations across Illinois, Missouri, New Jersey, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00086125's enrollment target sits among peer trials
57 139th of 299 higher than 160 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03521830 · 57 participants · Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- NCT03587701 · 57 participants · Phase 2
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
- NCT04104126 · 57 participants · NA
Blood Flow Restriction Therapy in Achilles Injury
- NCT04703842 · 57 participants · Phase 1
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia